` 214450 (PharmaResearch Co Ltd) vs KOSPI 200 Comparison - Alpha Spread

214450
vs
KOSPI 200

Over the past 12 months, has significantly outperformed KOSPI 200, delivering a return of 231% compared to the KOSPI 200's 4% drop.

Stocks Performance
214450 vs KOSPI 200

Loading

Performance Gap
214450 vs KOSPI 200

Loading
214450
KOSPI 200
Difference

Performance By Year
214450 vs KOSPI 200

Loading
214450
KOSPI 200
Add Stock

Competitors Performance
PharmaResearch Co Ltd vs Peers

KOSPI 200
214450
ABBV
AMGN
GILD
VRTX
Add Stock

PharmaResearch Co Ltd
Glance View

Market Cap
3.4T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

Intrinsic Value
343 320.59 KRW
Undervaluation 5%
Intrinsic Value
Price
P
Back to Top